Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BECTON DICKINSON & COBDX · Entity 2498 | Director | September 10, 2025 | September 11, 2025 |
| Seres Therapeutics, Inc.MCRB · Entity 7191 | Director | July 08, 2026 | July 10, 2026 |
| WATERS CORP /DE/WAT · Entity 3080 | Director | February 25, 2026 | February 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BECTON DICKINSON & CO
Report date September 10, 2025 · Filed September 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,226 |
Reported balance
After 2025-09-10 transaction · row 1
1 source rowRow 1 · 2025-09-10 · Sale · Disposed 917 · Balance 22,226 |
Seres Therapeutics, Inc.
Report date July 08, 2026 · Filed July 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.14 · Expires 2036-07-07 | Direct | 6,500 |
Reported balance
After 2026-07-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-08 · Grant · Acquired 6,500 · Balance 6,500 F1: The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026.
WATERS CORP /DE/
Report date February 25, 2026 · Filed February 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 489 |
Reported balance
After 2026-02-25 transaction · row 1
1 source rowRow 1 · 2026-02-25 · Grant · Acquired 358 · Balance 489 F1: Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $319.44 · Expires 2036-02-25 | Direct | 877 |
Reported balance
After 2026-02-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-25 · Grant · Acquired 877 · Balance 877 F2: All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027.
F2: All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 08, 2026 Filed Jul 10, 2026 16:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001193125-26-300921 · ownership.xml · derivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2036-07-07 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026. Read SEC document |
| February 25, 2026 Filed Feb 28, 2026 00:18 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantStock Option (Right to Buy) · Derivative | 877 | $0.00 Strike: $319.44 | $0.00 |
DisclosureSEC source: 0001000697-26-000077 · form4.xml · derivative · entry 2 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 877 Underlying: Common Stock · 877 shares Expires 2036-02-25 F2 · shares: All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027. Read SEC document |
| February 25, 2026 Filed Feb 28, 2026 00:18 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantCommon Stock | 358 | $0.00 | $0.00 |
DisclosureSEC source: 0001000697-26-000077 · form4.xml · nonDerivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 489 F1 · shares: Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027. Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 16:36 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 917 | $187.50 | $171,937.50 |
DisclosureSEC source: 0001382031-25-000007 · wk-form4_1757608610.xml · nonDerivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,226 Read SEC document |
| August 08, 2025 Filed Aug 8, 2025 22:56 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 863 | $192.30 | $165,954.90 |
DisclosureSEC source: 0000010795-25-000079 · wk-form4_1754693814.xml · nonDerivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,143 Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 17:34 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 6,452 | $0.00 Strike: $10.71 | $0.00 |
DisclosureSEC source: 0000950170-25-093273 · ownership.xml · derivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,452 Underlying: Common Stock · 6,452 shares Expires 2035-07-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in four equal quarterly installments occurring on October 1, 2025, January 1, 2026, April 1, 2026, and July 1, 2026, provided that if the issuer's 2026 annual meeting of stockholders occurs before July 1, 2026, the final quarterly vesting installment will vest on the day immediately prior to the date of such annual meeting, in each case, subject to the reporting person continuing in service on the Board as a non-employee director through the applicable vesting date. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0000950170-25-053249 · ownership.xml · derivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-04-09 F1 · derivative.exercise_date: The option vests in full on the earlier of April 10, 2026 or the day immediately prior to the company's 2026 annual meeting of shareholders. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 21:01 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 930 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-001301 · form4.xml · nonDerivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,006 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 16:45 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy · Derivative | 60,000 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0000950170-24-042655 · ownership.xml · derivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-04-03 F1 · derivative.exercise_date: The option vests in full on the earlier of April 4, 2025 or the day immediately prior to the company's 2025 annual meeting of shareholders. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:15 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 900 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-001303 · form4.xml · nonDerivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,696 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| August 28, 2023 Filed Aug 30, 2023 12:48 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 848 | $281.66 | $238,847.68 |
DisclosureSEC source: 0001062993-23-017239 · form4.xml · nonDerivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,608 F1 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 17:25 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0000899243-23-016401 · doc4.xml · derivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: The option will vest in full on the earlier of June 22, 2024 or the day immediately prior to the company's 2024 annual meeting of shareholders. Read SEC document |
| January 26, 2023 Filed Jan 26, 2023 23:05 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 848 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-001433 · form4.xml · nonDerivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,311 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 16:35 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 48,000 | $0.00 Strike: $5.47 | $0.00 |
DisclosureSEC source: 0000899243-23-001007 · doc4.xml · derivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2033-01-03 F1 · derivative.exercise_date: The option will vest in four equal installments on each anniversary of January 4, 2023 or in full immediately prior to the occurrence of a change in control. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 15:17 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 841 | $271.70 | $228,499.70 |
DisclosureSEC source: 0001062993-22-003419 · form4.xml · nonDerivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,556 F1 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 13:23 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 820 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-001641 · form4.xml · nonDerivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,397 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| August 18, 2021 Filed Aug 18, 2021 16:29 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 387 | $251.58 | $97,361.46 |
DisclosureSEC source: 0001543407-21-000031 · edgar.xml · nonDerivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,220 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $241.35 through $241.37. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| May 27, 2021 Filed May 28, 2021 13:57 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 390 | $241.36 | $94,130.40 |
DisclosureSEC source: 0001543407-21-000026 · edgar.xml · nonDerivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,607 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $241.35 through $241.37. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 13:57 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 829 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-21-000007 · edgar.xml · nonDerivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,997 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| May 08, 2020 Filed May 8, 2020 18:29 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 771 | $256.56 | $197,807.76 |
DisclosureSEC source: 0001543407-20-000032 · edgar.xml · nonDerivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,168 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $256.46 through $256.57. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| February 11, 2020 Filed Feb 11, 2020 20:17 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 700 | $258.70 | $181,090.00 |
DisclosureSEC source: 0001543407-20-000024 · edgar.xml · nonDerivative · entry 2 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,939 F1 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| February 11, 2020 Filed Feb 11, 2020 20:17 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 800 | $258.73 | $206,984.00 |
DisclosureSEC source: 0001543407-20-000024 · edgar.xml · nonDerivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,639 F1 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 13:18 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 765 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-20-000011 · edgar.xml · nonDerivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,439 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| August 07, 2019 Filed Aug 7, 2019 18:56 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 1,429 | $243.26 | $347,618.54 |
DisclosureSEC source: 0001543407-19-000037 · edgar.xml · nonDerivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,544 F1 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 17:15 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 923 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-19-000010 · edgar.xml · nonDerivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,842 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 15:22 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 941 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-18-000016 · edgar.xml · nonDerivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,639 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| January 24, 2017 Filed Jan 26, 2017 19:10 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 1,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-17-000006 · edgar.xml · nonDerivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,391 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.